Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm

Clinical Cancer Research

Volumn 17, Issue 19, 2011, Pages 6163-6173

  Agliano, Alice ^a,b   Martin Padura, Ines ^a   Marighetti, Paola ^a   Gregato, Giuliana ^a   Calleri, Angelica ^a   Prior, Celia ^b   Redrado, Miriam ^b   Calvo, Alfonso ^b   Bertolini, Francesco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; CYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 2 RECEPTOR GAMMA; LENALIDOMIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; PLATINUM COMPLEX; PREDNISONE; VINCRISTINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLASTIC NK CELL LYMPHOMA; BLOOD ANALYSIS; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER STEM CELL; CANCER SURVIVAL; CASE REPORT; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; THALIDOMIDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 80053525115     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0212     Document Type: Article

References (35)

1. Adachi M, Maeda K, Takekawa M, Hinoda Y, Imai K, Sugiyama S, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol 1994;47: 278-82. (Pubitemid 24372281)
2. + cutaneous neoplasms: a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol 1999;23:137-46.
3. Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res 1999;23:615-24. (Pubitemid 29243865)
4. Feuillard J, Jacob MC, Valensi F, Mayanadié M, Gressin R, Chaperot L, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002;99:1556-63. (Pubitemid 34533026)
5. Suzuki R, Nakamura S, Suzumiya J, Ichimura K, Ichikawa M, Ogata K, et al. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer 2005;104:1022-31. (Pubitemid 41170230)
6. + blastic tumors of skin. Blood 2003;101:5007-9.
7. + hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol 2007;128:445-53.
8. + precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002;26:852-62.
9. Liang X, Graham DK. Natural killer cell neoplasms. Cancer 2008; 112:1425-36. (Pubitemid 351441155)
10. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009;523-31.
11. Pattengale PK, Taylor CR. Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias. Am J Pathol 1983;113:237-65.
12. Lapidot T, Fajerman Y, Kollet O. Immune-deficient SCID and NOD/ SCID mice models as functional assays for studying normal and malignant human hematopoiesis. J Mol Med 1997;75:664-73. (Pubitemid 27412708)
13. Enns A, Haier J. Models for lymphoma. In: Alison MR, editor. The cancer handbook. 2nd ed. Chichester, West Sussex, United Kingdom: John Wiley & Sons Ltd.; 2007.
14. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007;7:118-30. (Pubitemid 46174859)
15. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36.
16. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6. (Pubitemid 29295864)
17. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87:1166-72. (Pubitemid 35418112)
18. Buesche G, Dieck S, Giagounidis A, Bock O, Wilkens L, Schlegelberger B, et al. Anti-angiogenic in vivo effect of lenalidomide (CC-5013) in myelodysplastic syndrome with del (5q) chromosome abnormality and its relation to the course of disease [abstract]. Blood 2005;106 suppl:113a, abstr 372.
19. Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002;168:4914-9. (Pubitemid 34495953)
20. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-6.
21. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22:1925-32.
22. Geitz H, Handt S, Zwingenberger Z. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213-21. (Pubitemid 26122649)
23. Bertolini F, Fusetti L, Rabascio C, Cinieri S, Martinelli G, Pruneri G. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non- Hodgkin's lymphoma. Leukemia 2000;14:1477-82. (Pubitemid 30601356)
24. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G, et al. Human acute leukemia cells injected in NOD/LtSzscid/ IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008;123:2222-7.
25. Philpott NJ, Turner AJ, Scopes J, Westby M, Marsh JC, Gordon-Smith EC, et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 1996;87:2244-51. (Pubitemid 26086863)
26. Li L, Yoon SO, Fu DD, Zhang X, Choi YS. Novel follicular dendritic cell molecule, 8D6, collaborates with CD44 in supporting lymphomagenesis by a Burkitt lymphoma cell line, L3055. Blood 2004; 104:815-21. (Pubitemid 38970579)
27. Hilmar MZ, Drexler HG. The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines. Leuk Res 1997;21:343-50. (Pubitemid 27197429)
28. Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010;116:4541-8.
29. Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O'Connor OA. Novel disease targets and management approaches for diffuse large B-cell lymphoma. Leuk Lymphoma 2010;51 Suppl 1:1-10.
30. Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C. Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 2009; 101:803-12.
31. Kotoh T, Dhar DK, Masunaga R, Tabara H, Tachibana M, Kubota H, et al. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 1999;125:536-44. (Pubitemid 29226926)
32. Kaicker S, McCrudden KW, Beck L, New T, Huang J, Frischer JS, et al. Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. Int J Oncol 2003;23:1651-5.
33. Blansfield JA, Caragacianu D, Alexander HR III, Tangrea MA, Morita SY, Lorang D, et al. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008;14:270-80. (Pubitemid 351384377)
34. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6. (Pubitemid 29295864)
35. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007;104:17069-74. (Pubitemid 350210993)